
  
    
      
        Background_NNP
        Meta-analysis_NNP has_VBZ been_VBN defined_VBN as_IN '_POS the_DT statistical_JJ
        analysis_NN of_IN a_DT large_JJ collection_NN of_IN analysis_NN results_NNS from_IN
        individual_JJ studies_NNS for_IN the_DT purpose_NN of_IN integrating_VBG the_DT
        findings_NNS ._. '_POS [_NN 1_CD ]_NN Although_IN there_EX has_VBZ always_RB been_VBN some_DT
        controversy_NN about_IN its_PRP$ validity_NN [_NN 2_CD 3_CD 4_CD 5_CD 6_CD 7_CD 8_CD ]_NN ,_,
        meta-analysis_JJ has_VBZ become_VBN increasingly_RB popular_JJ as_IN the_DT number_NN
        of_IN studies_NNS with_IN similar_JJ protocols_NNS has_VBZ grown_VBN ._. By_IN
        systematically_RB combining_VBG studies_NNS ,_, one_CD attempts_NNS to_TO overcome_VB
        limits_NNS of_IN size_NN or_CC scope_NN in_IN individual_JJ studies_NNS to_TO obtain_VB
        more_RBR reliable_JJ information_NN about_IN treatment_NN effects_NNS ._.
        A_DT meta-analysis_JJ goes_VBZ beyond_IN a_DT literature_NN review_NN ,_, in_IN
        which_WDT the_DT results_NNS of_IN the_DT various_JJ studies_NNS are_VBP discussed_VBN ,_,
        compared_VBN and_CC perhaps_RB tabulated_JJ ,_, since_IN it_PRP synthesizes_NNS the_DT
        results_NNS of_IN the_DT individual_JJ studies_NNS into_IN a_DT new_JJ result_NN ._. A_DT
        meta-analysis_JJ also_RB differs_VBZ from_IN a_NNP '_POS pooled_VBN data_NNS '_POS analysis_NN
        because_IN the_DT summary_NN results_NNS of_IN the_DT previous_JJ studies_NNS ,_, not_RB
        the_DT results_NNS on_IN individual_JJ subjects_NNS ,_, are_VBP combined_VBN for_IN
        analysis_NN ._.
        Meta-analyses_NNP are_VBP fairly_RB common_JJ in_IN some_DT fields_NNS of_IN
        research_NN and_CC are_VBP relatively_RB rare_JJ in_IN others_NNS ._. In_IN fact_NN ,_, a_DT
        March_NNP 2002_CD Medline_NNP search_NN revealed_VBD 1_CD ,_, 610_CD articles_NNS with_IN the_DT
        keyword_NN '_'' cancer_NN '_'' ,_, and_CC only_RB 19_CD with_IN the_DT keyword_NN COPD_NNP and_CC 41_CD
        with_IN the_DT keyword_NN '_'' epilepsy_NN '_'' among_IN the_DT 9_CD ,_, 055_CD articles_NNS
        indexed_VBN under_IN meta-analysis_JJ ._. This_DT may_MD reflect_VB a_DT common_JJ
        belief_NN that_IN meta-analyses_JJ should_MD be_VB based_VBN on_IN multiple_JJ
        clinical_JJ trials_NNS ,_, which_WDT are_VBP very_RB common_JJ in_IN cancer_NN studies_NNS
        and_CC less_RBR common_JJ in_IN other_JJ fields_NNS ._. However_RB ,_, a_DT meta-analysis_JJ
        of_IN small_JJ trials_NNS may_MD provide_VB sufficient_JJ information_NN on_IN
        treatment_NN effects_NNS to_TO avoid_VB the_DT delay_NN and_CC expense_NN of_IN a_DT
        large-scale_JJ randomized_JJ clinical_JJ trial_NN ._. If_IN proper_JJ methods_NNS
        for_IN selecting_VBG and_CC combining_VBG studies_NNS are_VBP used_VBN ,_, observational_NN
        studies_NNS can_MD also_RB be_VB included_VBN in_IN a_DT meta-analysis_JJ [_NN 9_CD 10_CD 11_CD ]_NN
        ._. Guidelines_NNS for_IN meta-analysis_JJ of_IN observational_NN studies_NNS
        have_VBP been_VBN published_VBN [_NN 12_CD ]_NN ._. In_IN particular_JJ ,_, meta-analysis_JJ
        may_MD be_VB used_VBN for_IN combining_VBG studies_NNS in_IN research_NN where_WRB
        clinical_JJ trials_NNS would_MD not_RB be_VB practical_JJ or_CC would_MD be_VB
        unethical_JJ ._.
        Because_IN a_DT meta-analysis_JJ does_VBZ not_RB involve_VB human_JJ subjects_NNS
        or_CC experimental_JJ animals_NNS directly_RB ,_, it_PRP is_VBZ often_RB considered_VBN an_DT
        easy_JJ study_NN that_WDT can_MD be_VB done_VBN with_IN a_DT minimum_NN of_IN effort_NN and_CC
        little_JJ attention_NN is_VBZ often_RB paid_VBN to_TO details_NNS of_IN design_NN and_CC
        implementation_NN ._. A_DT valid_JJ meta-analysis_JJ ,_, however_RB ,_, requires_VBZ
        the_DT same_JJ careful_JJ planning_NN as_IN any_DT other_JJ research_NN study_NN ._. In_IN
        this_DT paper_NN ,_, we_PRP will_MD focus_VB on_IN the_DT important_JJ design_NN issues_NNS
        underlying_VBG a_DT meta-analysis_JJ :_: formulating_VBG the_DT study_NN question_NN ,_,
        identification_NN of_IN research_NN studies_NNS ,_, collecting_VBG and_CC
        evaluating_VBG information_NN about_IN these_DT studies_NNS ,_, and_CC extracting_VBG
        results_NNS ._. Simple_NN methods_NNS for_IN analyzing_VBG the_DT data_NNS once_RB it_PRP is_VBZ
        collected_VBN are_VBP described_VBN briefly_NN ._.
      
      
        Methods_NNP
        
          Defining_VBG the_DT Objectives_NNP of_IN the_DT Study_NNP
          The_DT first_JJ step_NN is_VBZ to_TO identify_VB the_DT problem_NN ._. This_DT
          includes_VBZ specifying_VBG the_DT disease_NN or_CC condition_NN of_IN interest_NN ,_,
          the_DT population_NN of_IN interest_NN ,_, the_DT specific_JJ treatments_NNS or_CC
          exposures_NNS being_VBG studied_VBN and_CC the_DT outcome_NN measurements_NNS
          (_( efficacy_NN ,_, adverse_JJ reactions_NNS or_CC both_DT )_) being_VBG studied_VBN ._.
          Additional_JJ clinical_JJ or_CC biological_JJ measurements_NNS of_IN
          interest_NN that_WDT might_MD be_VB potential_JJ confounders_NNS of_IN the_DT
          results_NNS should_MD also_RB be_VB identified_VBN at_IN this_DT time_NN ,_, although_IN
          other_JJ factors_NNS may_MD be_VB recognized_VBN during_IN the_DT evaluation_NN or_CC
          data_NNS collection_NN phase_NN of_IN the_DT meta-analysis_JJ ._.
          The_DT goals_NNS of_IN the_DT study_NN should_MD be_VB defined_VBN at_IN this_DT
          stage_NN ._. Meta-analyses_NNP attempt_NN to_TO meet_VB one_CD or_CC both_DT of_IN two_CD
          goals_NNS :_: summarizing_VBG the_DT available_JJ data_NN or_CC explaining_VBG the_DT
          variability_NN between_IN different_JJ studies_NNS ._. When_WRB the_DT objective_NN
          is_VBZ to_TO summarize_VB the_DT effects_NNS of_IN an_DT intervention_NN ,_, ideally_RB
          all_DT studies_NNS would_MD have_VB similar_JJ patient_NN characteristics_NNS
          and_CC the_DT outcome_NN measures_NNS would_MD be_VB consistent_JJ across_IN
          studies_NNS ._. Thus_RB ,_, the_DT summary_NN measure_NN resulting_VBG from_IN the_DT
          meta-analysis_JJ would_MD reflect_VB the_DT effect_NN of_IN the_DT treatment_NN
          being_VBG studied_VBN ._. In_IN practice_NN ,_, however_RB ,_, there_EX is_VBZ always_RB
          variability_NN between_IN studies_NNS both_DT in_IN patient_NN
          characteristics_NNS and_CC in_IN outcome_NN measures_NNS ,_, which_WDT is_VBZ ,_, of_IN
          course_NN ,_, the_DT primary_JJ motivation_NN for_IN performing_VBG a_DT formal_JJ
          meta-analysis_JJ ._.
          Alternatively_RB ,_, one_PRP might_MD attempt_VB to_TO model_VB the_DT
          variability_NN between_IN studies_NNS to_TO understand_VB why_WRB different_JJ
          studies_NNS had_VBD different_JJ results_NNS [_NN 13_CD 14_CD ]_NN ._. This_DT would_MD
          suggest_VB that_IN as_IN wide_JJ a_DT range_NN of_IN studies_NNS should_MD be_VB
          included_VBN as_IN possible_JJ ._. Frequently_RB both_DT objectives_NNS can_MD be_VB
          served_VBN in_IN the_DT same_JJ meta-analysis_JJ ,_, by_IN providing_VBG summary_NN
          statistics_NNS of_IN treatment_NN or_CC exposure_NN effects_NNS in_IN subgroups_NNS ,_,
          often_RB referred_VBD to_TO as_IN a_DT sensitivity_NN analysis_NN ,_, and_CC modeling_VBG
          the_DT heterogeneity_NN across_IN studies_NNS as_IN a_DT function_NN of_IN patient_NN
          characteristics_NNS ._. Given_VBN the_DT amount_NN of_IN work_NN involved_VBN in_IN
          performing_VBG any_DT meta-analysis_JJ ,_, we_PRP recommend_VBP that_IN a_DT
          meta-analysis_JJ attempt_NN to_TO meet_VB both_DT these_DT goals_NNS ._.
        
        
          Defining_VBG the_DT Population_NNP of_IN Studies_NNPS Included_VBN in_IN the_DT
          Meta-_NNP Analysis_NNP
          Inclusion_NNP and_CC exclusion_NN criteria_NNS for_IN studies_NNS are_VBP as_IN
          necessary_JJ in_IN a_DT meta-analysis_JJ as_IN they_PRP are_VBP in_IN clinical_JJ
          studies_NNS to_TO safeguard_VB against_IN selection_NN bias_NN ._. These_DT
          criteria_NNS need_VBP to_TO be_VB specified_VBN in_IN the_DT meta-analysis_JJ
          protocol_NN ,_, just_RB as_IN inclusion_NN /_NN exclusion_NN criteria_NNS are_VBP
          specified_VBN in_IN a_DT clinical_JJ protocol_NN ._. The_DT criteria_NNS should_MD
          follow_VB immediately_RB from_IN the_DT objectives_NNS of_IN the_DT study_NN ._. An_DT
          analysis_NN aimed_VBN at_IN providing_VBG a_DT summary_NN result_NN in_IN a_DT
          specific_JJ subgroup_NN of_IN subjects_NNS will_MD necessarily_RB have_VB more_RBR
          restrictive_JJ criteria_NNS than_IN one_CD designed_VBN to_TO investigate_VB
          heterogeneity_NN ._. The_DT inclusion_NN criteria_NNS should_MD address_VB at_IN
          least_JJS the_DT following_VBG ._.
        
        
          Type_NNP of_IN study_NN
          Will_MD the_DT analysis_NN be_VB restricted_VBN to_TO randomized_JJ clinical_JJ
          trials_NNS only_RB ,_, or_CC will_MD other_JJ designs_NNS be_VB included_VBN ?_. In_IN our_PRP$
          opinion_NN ,_, trials_NNS other_JJ than_IN RCT_NNP are_VBP allowable_JJ ._. As_IN we_PRP
          mentioned_VBD in_IN the_DT introduction_NN ,_, there_EX is_VBZ some_DT disagreement_NN
          on_IN this_DT subject_JJ [_NN 5_CD 6_CD 9_CD 11_CD 12_CD 15_CD 16_CD ]_NN ._. The_DT type_NN of_IN study_NN
          may_MD be_VB used_VBN as_IN a_DT classification_NN variable_JJ in_IN a_DT sensitivity_NN
          analysis_NN or_CC in_IN assessing_VBG the_DT quality_NN of_IN the_DT study_NN as_IN
          described_VBN below_IN ._. Olkin_NNP [_NN 14_CD ]_NN has_VBZ developed_VBN a_DT hierarchy_NN
          of_IN strength_NN of_IN evidence_NN based_VBN on_IN the_DT type_NN of_IN design_NN ,_,
          ranging_VBG from_IN case_NN reports_NNS (_( the_DT weakest_JJS )_) to_TO randomized_JJ
          trials_NNS (_( the_DT strongest_JJS )_) ,_, with_IN case-control_JJ studies_NNS
          somewhere_RB in_IN the_DT middle_NN ._. This_DT hierarchy_NN may_MD serve_VB as_IN a_DT
          guideline_NN for_IN inclusion_NN of_IN different_JJ designs_NNS ._. Example_NN 3_CD [_NN
          17_CD ]_NN ,_, discussed_VBN below_IN ,_, shows_VBZ how_WRB a_DT valid_JJ meta-analysis_JJ
          may_MD be_VB based_VBN only_RB on_IN observational_NN studies_NNS when_WRB clinical_JJ
          trials_NNS would_MD not_RB be_VB ethical_JJ ._.
        
        
          Patient_NNP characteristics_NNS
          These_DT include_VBP age_NN ,_, gender_NN ,_, ethnicity_NN ,_, presenting_VBG
          condition_NN ,_, duration_NN of_IN illness_NN ,_, and_CC method_NN of_IN diagnosis_NN ._.
          Again_RB ,_, this_DT needs_VBZ to_TO reflect_VB the_DT goals_NNS of_IN the_DT study_NN ._. We_PRP
          recommend_VBP that_IN a_DT meta-analysis_JJ be_VB as_RB inclusive_JJ as_IN
          possible_JJ ,_, e_SYM ._. g_SYM ._. ,_, you_PRP may_MD exclude_VB studies_NNS in_IN children_NNS if_IN
          they_PRP are_VBP known_VBN to_TO be_VB different_JJ from_IN adults_NNS ,_, but_CC all_DT
          studies_NNS in_IN adults_NNS should_MD be_VB included_VBN without_IN regard_NN to_TO
          age_NN or_CC gender_NN ._. If_IN you_PRP limit_VBP the_DT meta-analysis_JJ to_TO a_DT very_RB
          restricted_VBN population_NN it_PRP will_MD probably_RB provide_VB little_RB new_JJ
          information_NN ._. We_PRP recommend_VBP including_VBG population_NN factors_NNS as_IN
          covariates_NNS in_IN estimates_NNS of_IN the_DT overall_JJ effect_NN and_CC
          examining_VBG their_PRP$ effects_NNS in_IN a_DT sensitivity_NN analysis_NN ._.
        
        
          Treatment_NNP modalities_NNS
          Allowable_NNP treatment_NN type_NN ,_, dosage_NN ,_, and_CC duration_NN of_IN
          treatment_NN should_MD be_VB addressed_VBN ._. Since_IN analysis_NN of_IN a_DT given_VBN
          treatment_NN is_VBZ frequently_RB the_DT reason_NN for_IN the_DT meta-analysis_JJ ,_,
          most_RBS meta-analyses_JJ are_VBP limited_VBN to_TO tests_NNS of_IN a_DT specific_JJ
          treatment_NN or_CC variations_NNS within_IN that_DT treatment_NN ,_, such_JJ as_IN
          formulation_NN ,_, route_NN of_IN delivery_NN ,_, or_CC dosage_NN ._. Variations_NNP in_IN
          treatment_NN may_MD be_VB deliberately_RB included_VBN for_IN comparison_NN or_CC
          for_IN sensitivity_NN analysis_NN ._. If_IN controlled_VBN studies_NNS are_VBP
          included_VBN ,_, then_RB these_DT criteria_NNS should_MD specify_VB the_DT
          acceptable_JJ control_NN groups_NNS ,_, e_SYM ._. g_SYM ._. ,_, placebo_NN control_NN or_CC a_DT
          standard_JJ treatment_NN ._. If_IN more_JJR than_IN one_CD standard_JJ treatment_NN
          can_MD be_VB used_VBN for_IN the_DT condition_NN being_VBG studied_VBN ,_, then_RB the_DT
          protocol_NN must_MD either_CC define_VB which_WDT ones_NNS will_MD be_VB acceptable_JJ
          or_CC methods_NNS to_TO address_VB this_DT possible_JJ source_NN of_IN variability_NN
          between_IN studies_NNS ._.
        
        
          Outcome_NNP measures_NNS
          Many_JJ studies_NNS have_VBP multiple_JJ outcome_NN measures_NNS ._. The_DT
          protocol_NN for_IN the_DT meta-analysis_JJ should_MD specify_VB the_DT outcome_NN
          measure_NN (_( s_VBZ )_) of_IN interest_NN ,_, including_VBG the_DT allowable_JJ methods_NNS
          of_IN measurement_NN ._. For_IN example_NN ,_, percent_NN body_NN fat_NN may_MD be_VB
          measured_VBN by_IN DEXA_NNP scan_VB ,_, by_IN underwater_JJ weighing_VBG ,_, by_IN
          bioimpedance_NN or_CC by_IN anthropometry_NN ._. Different_JJ methods_NNS of_IN
          measurement_NN ,_, if_IN allowed_VBN ,_, should_MD be_VB accounted_VBN for_IN in_IN the_DT
          analysis_NN ._. When_WRB allowed_VBN ,_, the_DT protocol_NN must_MD specify_VB whether_IN
          every_DT study_NN must_MD report_VB all_DT of_IN them_PRP ,_, any_DT one_CD of_IN them_PRP ,_, or_CC
          at_IN least_JJS one_CD or_CC two_CD specific_JJ ones_NNS ._. We_PRP recommend_VBP that_IN the_DT
          protocol_NN allow_VB only_RB one_CD or_CC two_CD primary_JJ outcomes_NNS to_TO focus_VB
          the_DT analysis_NN and_CC avoid_VB the_DT impression_NN of_IN a_DT fishing_NN
          expedition_NN ._. We_PRP realize_VBP that_IN once_RB the_DT studies_NNS have_VBP been_VBN
          located_VBN and_CC evaluated_VBN ,_, investigators_NNS are_VBP reluctant_JJ to_TO
          neglect_NN any_DT information_NN and_CC may_MD want_VB to_TO perform_VB
          additional_JJ analyses_NNS on_IN other_JJ outcomes_NNS ._. However_RB ,_, it_PRP is_VBZ
          likely_JJ that_IN not_RB all_DT studies_NNS relating_VBG to_TO these_DT other_JJ
          outcomes_NNS will_MD have_VB been_VBN obtained_VBN since_IN they_PRP were_VBD not_RB the_DT
          initial_JJ purpose_NN of_IN the_DT analysis_NN ._.
          An_DT important_JJ point_NN ,_, sometimes_RB neglected_VBN ,_, is_VBZ that_IN one_PRP
          should_MD include_VB only_RB one_CD set_NN of_IN results_NNS from_IN a_DT single_JJ
          study_NN ,_, even_RB if_IN multiple_JJ publications_NNS are_VBP available_JJ ._. Thus_RB ,_,
          it_PRP is_VBZ necessary_JJ to_TO have_VB a_DT method_NN for_IN deciding_VBG which_WDT
          paper_NN (_( s_VBZ )_) will_MD be_VB included_VBN ._. Most_JJS often_RB it_PRP is_VBZ reasonable_JJ to_TO
          specify_VB that_IN this_DT will_MD be_VB the_DT latest_JJS paper_NN published_VBD ,_, or_CC
          the_DT paper_NN with_IN the_DT most_RBS complete_JJ data_NNS on_IN the_DT outcome_NN
          measures_NNS of_IN interest_NN ._. In_IN any_DT case_NN ,_, the_DT decision_NN rule_NN
          needs_VBZ to_TO be_VB specified_VBN in_IN the_DT meta-analysis_JJ protocol_NN
          before_IN reviewing_VBG results_NNS in_IN the_DT papers_NNS so_IN that_DT selection_NN
          cannot_NN be_VB influenced_VBN by_IN the_DT results_NNS ._.
        
        
          Locating_NNP Studies_NNPS
          Locating_NNP 
          all_DT studies_NNS is_VBZ by_IN far_RB the_DT most_RBS
          difficult_JJ and_CC the_DT most_RBS frustrating_JJ aspect_NN of_IN any_DT
          meta-analysis_JJ but_CC it_PRP is_VBZ the_DT most_RBS important_JJ step_NN ._. A_DT
          structured_VBN plan_NN is_VBZ necessary_JJ to_TO manage_VB the_DT frequently_RB
          large_JJ number_NN of_IN papers_NNS ._. Most_JJS meta-analyses_JJ begin_VB with_IN a_DT
          search_NN using_VBG the_DT NLM_NNP Medline_NNP system_NN ._. This_DT should_MD be_VB
          supplemented_JJ by_IN the_DT use_NN of_IN other_JJ computerized_JJ indices_NNS ,_,
          such_JJ as_IN in-house_JJ research_NN listings_NNS and_CC reports_NNS from_IN
          professional_JJ organizations_NNS ._. Properly_NNP done_VBN ,_, this_DT will_MD give_VB
          you_PRP most_JJS of_IN the_DT 
          published_VBN articles_NNS relating_VBG to_TO your_PRP$
          topic_NN ._.
          There_EX are_VBP several_JJ options_NNS for_IN finding_VBG unpublished_JJ
          studies_NNS ._. Peer_NNP consultation_NN ,_, i_NNP ._. e_SYM ._. networking_NN among_IN your_PRP$
          professional_JJ colleagues_NNS and_CC contacting_VBG specific_JJ
          investigators_NNS who_WP are_VBP known_VBN to_TO be_VB active_JJ in_IN the_DT area_NN can_MD
          help_VB identify_VB additional_JJ studies_NNS and_CC investigators_NNS ._. Since_IN
          abstracts_NNS are_VBP often_RB not_RB included_VBN in_IN computer_NN indexes_NNS ,_, it_PRP
          is_VBZ necessary_JJ to_TO manually_RB review_VB special_JJ meeting_NN issues_NNS of_IN
          journals_NNS from_IN the_DT major_JJ professional_JJ organizations_NNS in_IN the_DT
          field_NN ._. In_IN addition_NN ,_, one_PRP might_MD publish_VB a_DT request_NN for_IN
          information_NN at_IN meetings_NNS and_CC in_IN newsletters_NNS ._. References_NNP to_TO
          '_POS unpublished_JJ data_NNS '_POS in_IN published_VBN studies_NNS must_MD be_VB followed_VBN
          up_RP ._. The_DT NIH_NNP and_CC NLM_NNP maintain_VBP registries_NNS of_IN clinical_JJ
          trials_NNS for_IN some_DT diseases_NNS ;_: public_JJ non-profit_JJ
          organizations_NNS ,_, such_JJ as_IN the_DT American_NNP Diabetes_NNP Association_NNP ,_,
          can_MD usually_RB supply_VB information_NN about_IN trials_NNS and_CC other_JJ
          studies_NNS that_IN they_PRP are_VBP sponsoring_VBG ._. The_DT Cochrane_NNP Library_NNP
          contains_VBZ a_DT bibliography_NN of_IN controlled_VBN trials_NNS as_RB well_RB as_IN
          abstracts_NNS of_IN reviews_NNS of_IN the_DT effects_NNS of_IN healthcare_NN ._. The_DT
          Internet_NN is_VBZ becoming_VBG increasingly_RB important_JJ for_IN
          identifying_VBG studies_NNS ,_, using_VBG resources_NNS such_JJ as_IN news_NN groups_NNS
          or_CC mailing_NN lists_NNS ._.
          In_IN meta-analysis_JJ ,_, one_CD is_VBZ particularly_RB concerned_VBN with_IN
          publication_NN bias_NN ,_, i_NNP ._. e_SYM ._. the_DT effect_NN of_IN failing_VBG to_TO detect_VB
          unpublished_JJ trials_NNS ._. The_DT most_RBS common_JJ reason_NN for_IN not_RB
          publishing_VBG is_VBZ nonsignificant_NN or_CC uninteresting_VBG results_NNS [_NN
          16_CD 18_CD ]_NN ._. Clearly_RB ,_, leaving_VBG out_IN negative_JJ studies_NNS in_IN any_DT
          meta-analysis_JJ will_MD substantially_RB bias_NN the_DT result_NN so_IN that_DT
          treatment_NN will_MD appear_VB more_RBR effective_JJ than_IN it_PRP actually_RB is_VBZ ._.
          Other_JJ factors_NNS associated_VBN with_IN failure_NN to_TO publish_VB include_VBP
          type_NN of_IN study_NN ,_, with_IN clinical_JJ trials_NNS being_VBG most_RBS likely_JJ to_TO
          be_VB published_VBN ,_, and_CC funding_NN source_NN ,_, with_IN externally_RB funded_VBN
          studies_NNS having_VBG a_DT higher_JJR publication_NN rate_NN ._. Olkin_NNP [_NN 14_CD ]_NN
          has_VBZ noted_VBN that_IN the_DT results_NNS of_IN very_RB large_JJ studies_NNS are_VBP
          usually_RB published_VBN whereas_IN the_DT publication_NN of_IN small_JJ
          studies_NNS may_MD depend_VB on_IN timing_NN ,_, with_IN early_JJ small_JJ studies_NNS
          having_VBG a_DT higher_JJR chance_NN of_IN publications_NNS than_IN later_RB small_JJ
          studies_NNS ._. Other_JJ causes_NNS of_IN publication_NN bias_NN include_VBP
          language_NN restrictions_NNS [_NN 13_CD 19_CD ]_NN and_CC imperfect_JJ search_NN
          techniques_NNS ._. For_IN the_DT later_RB ,_, we_PRP recommend_VBP that_IN
          investigators_NNS seek_VBP the_DT support_NN of_IN the_DT institutional_JJ
          librarians_NNS ._. Negative_JJ studies_NNS are_VBP more_RBR likely_JJ to_TO be_VB
          published_VBN in_IN '_POS local_JJ '_POS journals_NNS and_CC not_RB in_IN the_DT major_JJ
          international_JJ journals_NNS ,_, therefore_RB restricting_VBG language_NN to_TO
          English_NNP tends_VBZ to_TO exclude_VB negative_JJ studies_NNS done_VBN in_IN
          non-_NN English_NNP speaking_VBG countries_NNS [_NN 19_CD ]_NN ._. Unfortunately_RB ,_, it_PRP
          is_VBZ not_RB always_RB possible_JJ to_TO obtain_VB a_DT reliable_JJ translation_NN
          of_IN these_DT papers_NNS ._. Decisions_NNS regarding_VBG inclusion_NN of_IN papers_NNS
          in_IN a_DT foreign_JJ language_NN must_MD be_VB made_VBN before_IN one_CD begins_VBZ
          attempting_VBG to_TO locate_VB studies_NNS ._. Even_RB if_IN the_DT results_NNS of_IN such_JJ
          papers_NNS are_VBP not_RB included_VBN in_IN the_DT meta-analysis_JJ ,_, the_DT
          existence_NN of_IN such_JJ papers_NNS should_MD be_VB reported_VBN ._.
          We_PRP recommend_VBP that_IN all_DT relevant_JJ studies_NNS be_VB listed_VBN in_IN
          the_DT material_NN and_CC methods_NNS section_NN or_CC in_IN an_DT appendix_NN ,_, even_RB
          when_WRB it_PRP was_VBD not_RB possible_JJ to_TO formally_RB screen_VB and_CC evaluate_VB
          them_PRP in_IN the_DT meta-analysis_JJ ,_, so_IN that_IN the_DT reader_NN will_MD be_VB
          aware_JJ of_IN the_DT number_NN of_IN studies_NNS not_RB included_VBN in_IN the_DT formal_JJ
          meta-analysis_JJ ._.
        
        
          Screening_NNP and_CC Evaluation_NNP
          A_DT quick_JJ review_NN of_IN the_DT abstracts_NNS of_IN the_DT papers_NNS will_MD
          eliminate_VB those_DT that_WDT are_VBP clearly_RB not_RB relevant_JJ to_TO the_DT
          meta-analysis_JJ or_CC do_VBP not_RB meet_VB other_JJ criteria_NNS ,_, such_JJ as_IN
          study_NN design_NN ,_, specific_JJ population_NN ,_, duration_NN of_IN treatment_NN
          or_CC date_NN of_IN the_DT study_NN ._. If_IN the_DT published_VBN material_NN is_VBZ just_RB
          an_DT abstract_JJ ,_, there_EX must_MD be_VB sufficient_JJ information_NN to_TO
          evaluate_VB its_PRP$ quality_NN ._. There_EX must_MD also_RB be_VB summary_NN
          statistics_NNS to_TO put_VB into_IN the_DT meta-analysis_JJ ,_, available_JJ
          either_CC from_IN the_DT written_VBN material_NN or_CC in_IN writing_VBG from_IN the_DT
          investigator_NN ._. It_PRP is_VBZ essential_JJ that_IN when_WRB the_DT available_JJ
          written_VBN information_NN is_VBZ insufficient_JJ for_IN the_DT meta-analysis_JJ
          that_IN strenuous_JJ efforts_NNS be_VB made_VBN to_TO contact_VB the_DT principal_JJ
          investigator_NN to_TO obtain_VB the_DT needed_VBN information_NN in_IN order_NN to_TO
          reduce_VB the_DT effect_NN of_IN publication_NN bias_NN ._. This_DT becomes_VBZ even_RB
          more_RBR important_JJ for_IN material_NN that_WDT has_VBZ not_RB been_VBN formally_RB
          published_VBN ,_, which_WDT can_MD only_RB be_VB obtained_VBN from_IN the_DT principal_JJ
          investigator_NN ._.
          Assuming_VBG adequate_JJ information_NN is_VBZ available_JJ ,_, each_DT study_NN
          should_MD then_RB be_VB subjected_VBN to_TO a_DT structured_VBN review_NN of_IN the_DT
          quality_NN of_IN the_DT study_NN ._. Table_NNP 2_CD (_( see_VB additional_JJ file_NN :_: Table_NNP
          2_LS )_) summarizes_NNS the_DT major_JJ points_NNS that_WDT should_MD be_VB addressed_VBN
          in_IN this_DT evaluation_NN ._. Although_IN Table_NNP 2_CD is_VBZ a_DT model_NN of_IN an_DT
          evaluation_NN score_NN sheet_NN ,_, it_PRP has_VBZ not_RB been_VBN formally_RB tested_VBN
          or_CC externally_RB validated_JJ ._.
          The_DT items_NNS in_IN part_NN A_DT ,_, which_WDT address_VBP sources_NNS ,_, require_VB
          that_IN the_DT authors_NNS and_CC institutions_NNS ,_, etc_FW ._. ,_, be_VB known_VBN ._. These_DT
          questions_NNS should_MD be_VB answered_VBN by_IN raters_NNS not_RB involved_VBN in_IN
          the_DT assessment_NN of_IN the_DT methods_NNS ,_, who_WP would_MD prepare_VB a_DT score_NN
          sheet_NN for_IN each_DT study_NN giving_VBG only_RB the_DT answers_NNS to_TO these_DT
          questions_NNS ._. To_TO assure_VB an_DT unbiased_JJ review_NN ,_, the_DT items_NNS in_IN
          part_NN B_NNP should_MD be_VB assessed_VBN by_IN raters_NNS who_WP are_VBP blinded_JJ both_DT
          to_TO the_DT authors_NNS and_CC the_DT results_NNS of_IN the_DT study_NN ._. Personnel_NNP
          not_RB involved_VBD in_IN this_DT part_NN of_IN the_DT evaluation_NN should_MD
          prepare_VB copies_NNS of_IN the_DT papers_NNS with_IN the_DT sources_NNS ,_, results_NNS
          and_CC other_JJ information_NN that_WDT might_MD indicate_VB the_DT authors_NNS or_CC
          outcome_NN removed_VBN for_IN this_DT step_NN in_IN the_DT evaluation_NN [_NN 7_CD ]_NN ._.
          Although_IN an_DT investigator_NN might_MD feel_VB that_IN blinding_VBG is_VBZ not_RB
          feasible_JJ because_IN of_IN time_NN or_CC cost_NN ,_, lack_NN of_IN blinding_VBG
          potentially_RB leads_VBZ to_TO major_JJ biases_NNS in_IN the_DT evaluation_NN of_IN
          studies_NNS and_CC thus_RB the_DT extra_JJ effort_NN is_VBZ warranted_VBN [_NN 4_CD 7_CD 20_CD
          21_CD 22_CD 23_CD ]_NN ._. Failure_NN to_TO blind_JJ the_DT review_NN could_MD lead_VB to_TO
          biases_NNS similar_JJ to_TO those_DT in_IN a_DT record_NN review_NN when_WRB subjects_NNS
          are_VBP selected_VBN by_IN investigators_NNS who_WP are_VBP not_RB blinded_JJ to_TO the_DT
          outcomes_NNS of_IN interest_NN ._. However_RB ,_, there_EX may_MD be_VB some_DT studies_NNS
          that_WDT are_VBP very_RB well_RB known_VBN ,_, or_CC the_DT research_NN area_NN may_MD be_VB so_RB
          small_JJ ,_, that_IN any_DT suitable_JJ rater_NN will_MD know_VB the_DT authors_NNS
          and_CC /_NN or_CC the_DT results_NNS of_IN the_DT study_NN ._. When_WRB this_DT occurs_VBZ ,_,
          efforts_NNS should_MD still_RB be_VB made_VBN to_TO blind_JJ the_DT study_NN and_CC have_VBP
          the_DT study_NN methods_NNS rated_VBN by_IN individuals_NNS outside_IN the_DT area_NN
          of_IN interest_NN ,_, but_CC with_IN expertise_NN in_IN study_NN design_NN issues_NNS ._.
          Some_DT investigators_NNS feel_VBP that_IN the_DT evaluation_NN should_MD also_RB
          address_VB whether_IN the_DT conclusions_NNS of_IN the_DT study_NN are_VBP
          consistent_JJ with_IN the_DT data_NNS ._. We_PRP feel_VBP that_IN ,_, since_IN the_DT
          meta-analysis_JJ is_VBZ based_VBN on_IN the_DT data_NNS and_CC not_RB the_DT written_VBN
          conclusions_NNS ,_, that_IN this_DT comparison_NN would_MD only_RB be_VB
          meaningful_JJ when_WRB the_DT conclusions_NNS are_VBP so_RB far-fetched_JJ as_IN to_TO
          cast_VB doubt_NN on_IN the_DT accuracy_NN of_IN the_DT entire_JJ study_NN ._. Since_IN
          this_DT case_NN is_VBZ very_RB rare_JJ we_PRP have_VBP not_RB included_VBN this_DT item_NN in_IN
          Table_NNP 2_CD ._. If_IN conclusions_NNS are_VBP to_TO be_VB evaluated_VBN ,_, the_DT raters_NNS
          should_MD still_RB be_VB blinded_JJ as_IN to_TO the_DT identity_NN of_IN the_DT
          investigators_NNS ._.
          The_DT methods_NNS used_VBN in_IN these_DT '_POS de-identified_JJ '_POS papers_NNS
          should_MD be_VB evaluated_VBN by_IN at_IN least_JJS two_CD raters_NNS ,_, a_DT content_NN
          expert_NN who_WP is_VBZ knowledgeable_JJ in_IN the_DT subject_JJ matter_NN and_CC a_DT
          biostatistician_NN or_CC epidemiologist_NN who_WP can_MD evaluate_VB the_DT
          analytic_JJ methods_NNS ._. We_PRP strongly_RB recommend_VBP the_DT use_NN of_IN a_DT
          numeric_JJ quality_NN score_NN to_TO summarize_VB the_DT results_NNS of_IN the_DT
          evaluation_NN [_NN 5_CD 20_CD 22_CD 24_CD ]_NN ._. The_DT two_CD blinded_JJ raters_NNS will_MD
          create_VB a_DT consensus_NN score_NN for_IN quality_NN which_WDT will_MD be_VB
          combined_VBN with_IN the_DT score_NN for_IN sources_NNS from_IN the_DT unblinded_JJ
          raters_NNS to_TO give_VB a_DT final_JJ score_NN for_IN the_DT study_NN ._. The_DT structure_NN
          and_CC items_NNS for_IN the_DT quality_NN score_NN must_MD be_VB specified_VBN in_IN the_DT
          meta-analysis_JJ protocol_NN and_CC should_MD only_RB be_VB modified_VBN if_IN
          some_DT items_NNS are_VBP missing_VBG in_IN all_DT studies_NNS ._. The_DT score_NN should_MD
          be_VB based_VBN on_IN the_DT items_NNS in_IN Table_NNP 2_CD ,_, but_CC may_MD be_VB modified_VBN to_TO
          suit_VB the_DT particular_JJ application_NN ._. Most_JJS of_IN the_DT items_NNS in_IN
          Part_NN A_DT and_CC all_DT of_IN the_DT items_NNS in_IN Part_NNP B_NNP can_MD be_VB answered_VBN as_IN
          '_POS Yes_UH '_POS ,_, '_'' No_NNP '_POS or_CC '_POS not_RB applicable_JJ '_'' ._. Since_IN many_JJ of_IN the_DT
          criteria_NNS ask_VBP whether_IN or_CC not_RB specific_JJ items_NNS of_IN information_NN
          are_VBP in_IN the_DT paper_NN ,_, if_IN one_CD of_IN these_DT items_NNS is_VBZ not_RB in_IN the_DT
          publication_NN and_CC is_VBZ not_RB available_JJ from_IN the_DT investigator_NN it_PRP
          is_VBZ coded_VBN as_IN '_POS No_NNP '_POS ,_, not_RB '_POS missing_VBG '_'' ._. Thus_RB ,_, the_DT number_NN of_IN '_POS not_RB
          applicable_JJ '_POS or_CC '_POS missing_VBG '_POS items_NNS should_MD be_VB small_JJ ._. For_IN
          example_NN ,_, if_IN the_DT demographic_JJ information_NN for_IN some_DT or_CC all_DT
          subject_JJ groups_NNS is_VBZ not_RB available_JJ ,_, the_DT response_NN to_TO the_DT
          third_JJ question_NN under_IN "_'' Study_NNP Subjects_NNP "_'' in_IN Table_NNP 2_CD would_MD be_VB
          '_POS No_NNP '_'' ._. If_IN this_DT information_NN was_VBD not_RB given_VBN ,_, you_PRP might_MD not_RB be_VB
          able_JJ to_TO answer_VB the_DT first_JJ question_NN in_IN Table_NNP 2_CD under_IN
          "_'' Controls_NNP "_'' ,_, which_WDT would_MD truly_RB be_VB missing_VBG information_NN ._. We_PRP
          recommend_VBP that_IN this_DT type_NN of_IN missing_VBG data_NNS also_RB be_VB coded_VBN as_IN
          '_POS No_NNP '_'' ._. If_IN critical_JJ information_NN is_VBZ missing_VBG ,_, such_JJ as_IN summary_NN
          statistics_NNS ,_, the_DT investigators_NNS should_MD contact_VB the_DT authors_NNS
          to_TO try_VB to_TO get_VB this_DT information_NN and_CC ,_, if_IN it_PRP is_VBZ not_RB
          available_JJ ,_, then_RB the_DT study_NN should_MD be_VB excluded_VBN from_IN the_DT
          meta-analysis_JJ ._. The_DT total_JJ score_NN may_MD be_VB based_VBN on_IN the_DT sum_NN of_IN
          individual_JJ items_NNS by_IN scoring_VBG 1_CD for_IN yes_UH and_CC 0_CD for_IN no_DT
          (_( reversed_VBD when_WRB necessary_JJ for_IN consistency_NN )_) then_RB expressing_VBG
          the_DT total_NN as_IN the_DT percent_NN of_IN the_DT maximum_NN possible_JJ ._. The_DT
          latter_JJ will_MD account_VB for_IN items_NNS coded_VBN as_IN '_POS not_RB applicable_JJ '_'' ._.
          Alternately_NNP ,_, the_DT investigators_NNS may_MD generate_VB a_DT summary_NN
          score_NN for_IN each_DT group_NN of_IN items_NNS and_CC use_NN either_CC the_DT sum_NN or_CC
          average_NN of_IN these_DT ._. The_DT former_JJ method_NN gives_VBZ equal_JJ weight_NN to_TO
          each_DT item_NN in_IN the_DT table_NN ,_, while_IN the_DT latter_JJ gives_VBZ equal_JJ
          weight_NN to_TO the_DT categories_NNS but_CC the_DT importance_NN of_IN each_DT item_NN
          varies_VBZ with_IN the_DT number_NN of_IN items_NNS in_IN a_DT category_NN ._.
          The_DT choice_NN of_IN method_NN may_MD depend_VB on_IN the_DT proposed_VBN use_NN of_IN
          the_DT quality_NN score_NN ,_, which_WDT must_MD also_RB be_VB specified_VBN in_IN the_DT
          protocol_NN [_NN 5_CD 20_CD 22_CD ]_NN ._. There_EX is_VBZ no_DT consensus_NN on_IN this_DT
          issue_NN in_IN the_DT meta-analysis_JJ literature_NN ._. Quality_JJ scores_NNS can_MD
          be_VB used_VBN in_IN several_JJ ways_NNS :_: as_IN a_DT cutoff_NN ,_, with_IN the_DT
          meta-analysis_JJ including_VBG only_RB studies_VBZ above_IN some_DT minimum_JJ
          score_NN ;_: as_IN a_DT weighting_NN value_NN ,_, with_IN studies_NNS with_IN higher_JJR
          quality_NN scores_NNS being_VBG given_VBN more_JJR weight_NN in_IN the_DT analysis_NN ;_:
          or_CC as_IN a_DT descriptive_JJ characteristic_NN of_IN the_DT study_NN ,_, used_VBN in_IN
          explaining_VBG study_NN variability_NN and_CC heterogeneity_NN ._. We_PRP
          recommend_VBP that_IN both_DT the_DT score_NN based_VBN on_IN items_NNS and_CC the_DT
          summary_NN score_NN be_VB computed_JJ ._. The_DT latter_NN should_MD be_VB used_VBN to_TO
          define_VB a_DT minimum_JJ value_NN below_IN which_WDT a_DT study_NN would_MD be_VB
          excluded_VBN from_IN the_DT analysis_NN ;_: the_DT former_JJ can_MD then_RB be_VB used_VBN
          to_TO rank_VB studies_NNS into_IN three_CD quality_NN groups_NNS as_IN a_DT means_NN of_IN
          assessing_VBG heterogeneity_NN between_IN studies_NNS ._. If_IN the_DT number_NN of_IN
          studies_NNS is_VBZ very_RB large_JJ ,_, then_RB more_JJR than_IN 3_CD groups_NNS may_MD be_VB
          used_VBN ._. If_IN the_DT number_NN of_IN studies_NNS is_VBZ small_JJ then_RB creating_VBG
          quality_NN groups_NNS is_VBZ not_RB possible_JJ and_CC only_RB the_DT summary_NN score_NN
          need_VBP be_VB computed_JJ ._. We_PRP do_VBP not_RB recommend_VB using_VBG the_DT quality_NN
          score_NN as_IN a_DT weighting_NN variable_JJ because_IN we_PRP feel_VBP it_PRP is_VBZ too_RB
          subjective_JJ ._. The_DT distribution_NN of_IN quality_NN scores_NNS may_MD be_VB
          addressed_VBN in_IN the_DT discussion_NN section_NN of_IN the_DT publication_NN ,_,
          as_IN noted_VBN below_IN ._.
          There_EX are_VBP other_JJ examples_NNS of_IN quality_NN scores_NNS in_IN the_DT
          literature_NN ._. Chalmers_NNP [_NN 25_CD ]_NN gives_VBZ a_DT comprehensive_JJ
          instrument_NN for_IN scoring_VBG a_DT randomized_JJ clinical_JJ trial_NN with_IN
          detailed_JJ questions_NNS on_IN every_DT aspect_NN of_IN a_DT trial_NN ,_, and_CC
          assigns_VBZ weights_NNS to_TO the_DT different_JJ sections_NNS ._. Although_IN it_PRP is_VBZ
          specifically_RB aimed_VBN at_IN RCT_NNP 's_POS ,_, it_PRP could_MD be_VB adapted_VBN to_TO other_JJ
          types_NNS of_IN studies_NNS ._. Other_JJ authors_NNS use_VBP greatly_RB reduced_VBD
          versions_NNS [_NN 11_CD 22_CD 26_CD ]_NN ._. A_DT bibliography_NN of_IN scales_NNS and_CC
          checklists_NNS is_VBZ given_VBN by_IN Moher_NNP [_NN 27_CD ]_NN ._.
        
        
          Data_NNP Abstraction_NNP
          Data_NNP should_MD be_VB abstracted_JJ onto_IN structured_VBN forms_NNS
          designed_VBN to_TO capture_VB relevant_JJ information_NN in_IN a_DT concise_NN ,_,
          focused_VBN fashion_NN ._. The_DT protocol_NN should_MD specify_VB the_DT items_NNS ,_,
          the_DT information_NN to_TO be_VB collected_VBN for_IN each_DT item_NN and_CC the_DT
          format_NN for_IN collecting_VBG the_DT items_NNS ._. Detailed_NNP instructions_NNS
          for_IN data_NNS extraction_NN and_CC completion_NN of_IN the_DT form_NN should_MD be_VB
          prepared_VBN ._. For_IN example_NN ,_, will_MD age_NN be_VB recorded_VBN as_IN the_DT range_NN ,_,
          mean_VB and_CC standard_JJ error_NN ,_, or_CC both_DT ?_. If_IN recoding_VBG or_CC
          estimation_NN is_VBZ required_VBN ,_, e_SYM ._. g_SYM ._. ,_, estimates_NNS of_IN the_DT standard_JJ
          deviation_NN from_IN the_DT range_NN ,_, the_DT algorithm_NN should_MD be_VB
          specified_VBN ._. Since_IN there_EX is_VBZ not_RB much_JJ consistency_NN with_IN
          respect_NN to_TO use_NN of_IN the_DT standard_JJ deviation_NN versus_CC the_DT
          standard_JJ error_NN ,_, the_DT protocol_NN should_MD specify_VB which_WDT should_MD
          be_VB used_VBN and_CC how_WRB to_TO convert_VB from_IN one_CD to_TO the_DT other_JJ ._. Other_JJ
          criteria_NNS include_VBP whether_IN rates_NNS will_MD be_VB entered_VBN as_IN
          proportions_NNS (_( less_JJR than_IN or_CC equal_JJ 1_LS )_) or_CC as_IN percents_NNS ,_,
          whether_IN natural_JJ logarithms_NNS or_CC base_NN 10_CD logarithms_NNS are_VBP
          used_VBN ,_, etc_FW ._. If_IN data_NNS are_VBP incomplete_JJ ,_, this_DT should_MD be_VB noted_VBN
          on_IN the_DT form_NN ,_, although_IN often_RB if_IN too_RB much_JJ data_NNS are_VBP missing_VBG
          the_DT study_NN will_MD be_VB excluded_VBN from_IN the_DT analysis_NN ._. Some_DT texts_NNS
          give_VBP formulas_NNS for_IN converting_VBG one_CD test_NN statistic_NN to_TO
          another_DT [_NN 28_CD ]_NN ;_: if_IN these_DT are_VBP to_TO be_VB used_VBN they_PRP should_MD be_VB
          clearly_RB defined_VBN in_IN the_DT instructions_NNS for_IN data_NNS extraction_NN ._.
          Ideally_RB two_CD individuals_NNS should_MD independently_RB abstract_JJ the_DT
          results_NNS from_IN every_DT study_NN and_CC differences_NNS resolved_VBN by_IN
          consensus_NN ._. Some_DT investigators_NNS recommend_VBP that_IN these_DT
          individuals_NNS be_VB blinded_JJ to_TO the_DT authors_NNS of_IN the_DT paper_NN [_NN 21_CD ]_NN
          ,_, however_RB ,_, if_IN the_DT criteria_NNS for_IN data_NNS collection_NN are_VBP
          objective_NN ,_, blinding_VBG of_IN abstractors_NNS ,_, although_IN not_RB
          essential_JJ ,_, is_VBZ still_RB desirable_JJ ._.
          The_DT data_NNS abstraction_NN form_NN should_MD be_VB headed_VBN with_IN a_DT
          study_NN number_NN ,_, if_IN blinding_VBG is_VBZ to_TO be_VB preserved_VBN ,_, or_CC with_IN the_DT
          name_NN of_IN the_DT study_NN ,_, the_DT publication_NN or_CC source_NN of_IN data_NNS ,_, the_DT
          name_NN and_CC affiliation_NN of_IN the_DT investigators_NNS ,_, and_CC the_DT type_NN
          of_IN design_NN ._. There_EX should_MD be_VB descriptions_NNS of_IN the_DT study_NN
          groups_NNS ,_, including_VBG number_NN of_IN groups_NNS ,_, size_NN of_IN group_NN ,_, age_NN ,_,
          gender_NN distribution_NN ,_, diagnoses_NNS ,_, treatments_NNS (_( including_VBG
          placebo_NN )_) ,_, other_JJ treatment_NN or_CC descriptive_JJ variables_NNS ,_, and_CC
          length_NN of_IN treatment_NN ._. The_DT summary_NN of_IN the_DT results_NNS can_MD be_VB
          quite_RB extensive_JJ ,_, including_VBG descriptive_JJ statistics_NNS for_IN all_DT
          groups_NNS and_CC all_DT outcome_NN measures_NNS ._. Differences_NNS between_IN
          groups_NNS in_IN time_NN ,_, dosage_NN ,_, etc_FW ._. should_MD be_VB included_VBN in_IN the_DT
          information_NN on_IN the_DT data_NNS abstraction_NN form_NN ._. The_DT test_NN
          statistics_NNS should_MD be_VB identified_VBN by_IN type_NN ,_, and_CC given_VBN along_IN
          with_IN the_DT p_NN value_NN ,_, the_DT sample_NN size_NN and_CC the_DT degrees_NNS of_IN
          freedom_NN when_WRB appropriate_JJ ._. Details_NNS of_IN statistical_JJ models_NNS
          need_VBP to_TO be_VB given_VBN ,_, listing_VBG other_JJ variables_NNS included_VBN in_IN the_DT
          model_NN ._.
          Space_NNP for_IN comments_NNS should_MD be_VB included_VBN ._. Table_NNP 3_CD (_( see_VB
          additional_JJ file_NN :_: Table_NNP 3_LS )_) is_VBZ an_DT example_NN of_IN a_DT data_NNS
          collection_NN form_NN for_IN a_DT meta-analysis_JJ of_IN a_DT clinical_JJ trial_NN
          with_IN 2_CD groups_NNS where_WRB one_CD outcome_NN is_VBZ a_DT continuous_JJ variable_JJ
          and_CC a_DT second_JJ outcome_NN is_VBZ a_DT proportion_NN ._. We_PRP strongly_RB
          recommend_VBP pilot_NN testing_VBG the_DT data_NNS abstraction_NN form_NN on_IN a_DT
          few_JJ studies_NNS before_IN defining_VBG a_DT final_JJ format_NN ._.
        
        
          Data_NNP Analysis_NNP
          Specific_JJ methods_NNS for_IN data_NNS analysis_NN in_IN meta-analysis_JJ
          have_VBP been_VBN developed_VBN and_CC are_VBP available_JJ in_IN many_JJ texts_NNS and_CC
          articles_NNS ._. The_DT book_NN by_IN Hedges_NNP and_CC Olkin_NNP [_NN 28_CD ]_NN has_VBZ been_VBN
          considered_VBN the_DT standard_JJ text_NN since_IN its_PRP$ publication_NN in_IN
          1985_CD ._. The_DT book_NN by_IN Wolf_NNP [_NN 29_CD ]_NN is_VBZ a_DT more_RBR accessible_JJ
          reference_NN at_IN a_DT basic_JJ level_NN that_WDT gives_VBZ formulas_NNS and_CC
          procedures_NNS for_IN simple_JJ studies_NNS ._. There_EX are_VBP also_RB many_JJ
          articles_NNS on_IN how_WRB to_TO do_VB meta-analysis_JJ ._. The_DT review_NN article_NN
          by_IN Fleiss_NNP [_NN 30_CD ]_NN is_VBZ reasonably_RB accessible_JJ for_IN a_DT
          non-mathematician_JJ who_WP is_VBZ not_RB frightened_JJ of_IN formulas_NNS ._. This_DT
          section_NN is_VBZ intended_VBN to_TO describe_VB the_DT general_JJ approach_NN to_TO
          the_DT statistical_JJ analysis_NN of_IN the_DT summary_NN data_NN that_WDT were_VBD
          collected_VBN ._. It_PRP is_VBZ not_RB intended_VBN to_TO give_VB instructions_NNS on_IN how_WRB
          to_TO do_VB the_DT actual_JJ computations_NNS ._. We_PRP recommend_VBP that_IN you_PRP work_VBP
          with_IN a_DT statistician_NN who_WP is_VBZ knowledgeable_JJ about_IN
          meta-analysis_JJ for_IN the_DT formal_JJ analysis_NN of_IN the_DT results_NNS ._.
          The_DT simplest_JJS method_NN is_VBZ to_TO use_VB a_DT weighted_JJ average_NN of_IN
          the_DT effects_NNS of_IN each_DT study_NN ._. The_DT analysis_NN is_VBZ usually_RB based_VBN
          on_IN a_DT summary_NN statistic_NN derived_VBN from_IN the_DT study_NN ,_, often_RB
          referred_VBD to_TO as_IN the_DT effect_NN size_NN and_CC a_DT weight_NN ,_, which_WDT in_IN
          most_JJS cases_NNS is_VBZ the_DT inverse_NN of_IN the_DT variance_NN of_IN the_DT effect_NN
          size_NN and_CC is_VBZ usually_RB related_VBN to_TO the_DT sample_NN size_NN ._. The_DT Q_NNP
          statistic_NN [_NN 28_CD ]_NN is_VBZ a_DT test_NN of_IN homogeneity_NN between_IN
          studies_NNS ._. A_DT large_JJ value_NN of_IN Q_NNP indicates_VBZ that_IN there_EX is_VBZ
          significant_JJ heterogeneity_NN between_IN studies_NNS ._. Petitti_NNP [_NN 31_CD ]_NN
          has_VBZ observed_VBN that_IN this_DT test_NN is_VBZ conservative_JJ ,_, and_CC we_PRP
          recommend_VBP that_IN the_DT significance_NN level_NN for_IN this_DT statistic_NN
          be_VB set_VBN to_TO 0_CD ._. 10_CD rather_RB than_IN the_DT usual_JJ 0_CD ._. 05_CD ._.
          Some_DT analysts_NNS might_MD try_VB to_TO reduce_VB the_DT heterogeneity_NN by_IN
          limiting_VBG the_DT meta-analysis_JJ to_TO a_DT smaller_JJR more_RBR homogeneous_JJ
          group_NN of_IN studies_NNS ._. However_RB ,_, this_DT limits_VBZ the_DT scope_NN of_IN the_DT
          meta-analysis_JJ and_CC essentially_RB throws_VBZ away_RB useful_JJ
          information_NN ._. Models_NNP that_WDT incorporate_VB and_CC evaluate_VB sources_NNS
          of_IN heterogeneity_NN are_VBP available_JJ ._. The_DT standard_JJ approach_NN is_VBZ
          the_DT random_JJ effects_NNS model_NN developed_VBN by_IN DerSimonian_NNP and_CC
          Laird_NNP [_NN 32_CD ]_NN and_CC is_VBZ well_RB described_VBN in_IN their_PRP$ paper_NN ._. Fleiss_NNP
          [_NN 30_CD ]_NN also_RB includes_VBZ these_DT methods_NNS as_IN alternative_JJ methods_NNS
          of_IN analysis_NN in_IN his_PRP$ paper_NN ._. Berlin_JJ [_NN 33_CD ]_NN and_CC Biggerstaff_NNP [_NN
          34_CD ]_NN expand_VB on_IN these_DT methods_NNS ._. There_EX is_VBZ some_DT controversy_NN
          about_IN the_DT use_NN of_IN these_DT models_NNS ._. Villar_NNP [_NN 35_CD ]_NN ,_, in_IN a_DT study_NN
          of_IN 84_CD independent_JJ meta-analyses_JJ of_IN randomized_JJ clinical_JJ
          trials_NNS ,_, showed_VBD that_IN in_IN meta-analyses_JJ where_WRB there_EX was_VBD a_DT
          significant_JJ value_NN of_IN the_DT Q_NNP statistic_NN ,_, the_DT use_NN of_IN random_JJ
          effects_NNS models_NNS showed_VBD wider_JJR confidence_NN intervals_NNS for_IN the_DT
          effects_NNS in_IN question_NN ,_, but_CC also_RB showed_VBD a_DT larger_JJR treatment_NN
          effect_NN ._. Petitti_NNP [_NN 31_CD ]_NN does_VBZ not_RB see_VB a_DT clear_JJ rationale_NN for_IN
          choosing_VBG between_IN a_DT random_JJ or_CC fixed_VBN effects_NNS model_NN ._. The_DT
          choice_NN of_IN analytic_JJ methods_NNS for_IN any_DT but_CC the_DT simplest_JJS
          situation_NN requires_VBZ input_NN from_IN a_DT statistician_NN experienced_VBN
          in_IN meta-analysis_JJ ._.
        
        
          Reporting_NNP and_CC Interpretation_NNP
          The_DT protocol_NN should_MD indicate_VB how_WRB the_DT results_NNS of_IN the_DT
          meta-analysis_JJ will_MD be_VB presented_VBN ._. We_PRP recognize_VBP that_RB ,_, like_IN
          the_DT data_NNS analysis_NN ,_, this_DT preliminary_JJ plan_NN may_MD be_VB modified_VBN
          during_IN the_DT implementation_NN of_IN the_DT study_NN ._. The_DT published_VBN
          meta-analysis_JJ should_MD include_VB a_DT table_NN containing_VBG all_DT
          relevant_JJ descriptive_JJ information_NN about_IN each_DT of_IN the_DT papers_NNS
          that_WDT are_VBP included_VBN in_IN the_DT analysis_NN in_IN a_DT table_NN ._. Ideally_RB ,_,
          all_DT articles_NNS reviewed_VBN would_MD be_VB described_VBN ,_, but_CC this_DT is_VBZ not_RB
          always_RB practical_JJ ,_, particularly_RB if_IN the_DT number_NN is_VBZ large_JJ and_CC
          many_JJ of_IN them_PRP are_VBP irrelevant_JJ ._. Effect_NN sizes_NNS ,_, odds_NNS ratios_NNS ,_,
          etc_FW are_VBP considered_VBN results_NNS and_CC may_MD be_VB presented_VBN in_IN
          summary_NN form_NN or_CC displayed_VBN for_IN individual_JJ studies_NNS ._.
          Graphical_NNP displays_NNS are_VBP very_RB helpful_JJ for_IN showing_VBG the_DT
          dispersion_NN of_IN single_JJ effects_NNS ._. All_DT the_DT examples_NNS described_VBD
          in_IN the_DT next_JJ section_NN have_VBP good_JJ examples_NNS of_IN graphical_JJ
          displays_NNS ._.
          With_IN respect_NN to_TO interpretation_NN ,_, we_PRP wish_VBP to_TO emphasize_VB
          two_CD points_NNS ._. The_DT first_JJ is_VBZ the_DT difference_NN between_IN
          statistical_JJ significance_NN and_CC clinical_JJ importance_NN ._. Most_JJS of_IN
          the_DT techniques_NNS for_IN meta-analysis_JJ will_MD give_VB a_DT p-value_JJ ,_, but_CC
          these_DT results_NNS must_MD be_VB interpreted_VBN in_IN light_NN of_IN the_DT other_JJ
          characteristics_NNS of_IN the_DT study_NN ._. The_DT distribution_NN of_IN quality_NN
          scores_NNS for_IN the_DT studies_NNS also_RB should_MD be_VB considered_VBN when_WRB
          deciding_VBG how_WRB much_JJ emphasis_NN to_TO give_VB to_TO the_DT results_NNS ._. If_IN the_DT
          quality_NN scores_NNS are_VBP skewed_VBN to_TO low_JJ values_NNS ,_, then_RB this_DT should_MD
          at_IN least_JJS be_VB mentioned_VBN in_IN the_DT discussion_NN as_IN a_DT possible_JJ
          shortcoming_NN of_IN the_DT meta-analysis_JJ ._. If_IN the_DT studies_NNS were_VBD
          almost_RB all_DT of_IN high_JJ quality_NN ,_, then_RB this_DT gives_VBZ more_JJR credence_NN
          to_TO the_DT results_NNS of_IN the_DT meta-analysis_JJ ._. The_DT second_JJ point_NN is_VBZ
          the_DT possible_JJ effect_NN of_IN unpublished_JJ studies_NNS on_IN
          statistically_RB significant_JJ results_NNS ._. Formulas_NNP for_IN
          estimating_VBG the_DT number_NN of_IN unpublished_JJ negative_JJ studies_NNS
          that_WDT would_MD be_VB necessary_JJ to_TO cast_VB doubt_NN on_IN the_DT results_NNS of_IN
          the_DT meta-analysis_JJ have_VBP been_VBN developed_VBN [_NN 36_CD 37_CD ]_NN ._.
          Obviously_RB ,_, if_IN this_DT number_NN were_VBD small_JJ ,_, then_RB the_DT results_NNS of_IN
          the_DT meta-analysis_JJ are_VBP less_RBR credible_JJ ._. On_IN the_DT other_JJ hand_NN if_IN
          this_DT number_NN is_VBZ large_JJ ,_, the_DT results_NNS of_IN the_DT meta-analysis_JJ
          are_VBP likely_JJ to_TO be_VB valid_JJ ._. We_PRP recommend_VBP that_IN the_DT
          investigator_NN compute_VB this_DT value_NN and_CC include_VBP the_DT results_NNS
          in_IN the_DT interpretation_NN of_IN the_DT findings_NNS ._.
        
      
      
        Results_NNS
        
          Objectives_NNP
          The_DT first_JJ three_CD articles_NNS attempted_VBD to_TO estimate_VB effects_NNS
          of_IN treatment_NN or_CC exposure_NN on_IN survival_NN (_( example_NN 1_LS )_) ,_, group_NN
          differences_NNS on_IN outcome_NN scores_NNS (_( example_NN 2_LS )_) or_CC relative_JJ
          risk_NN (_( example_NN 3_LS )_) ._. The_DT objective_NN of_IN the_DT fourth_JJ paper_NN was_VBD
          to_TO explore_VB the_DT effect_NN of_IN different_JJ approaches_NNS to_TO study_VB
          design_NN on_IN the_DT study_NN results_NNS ._. We_PRP do_VBP not_RB address_VB the_DT actual_JJ
          clinical_JJ criteria_NNS used_VBN in_IN these_DT studies_NNS ,_, as_IN that_DT is_VBZ not_RB
          relevant_JJ to_TO our_PRP$ paper_NN ,_, but_CC all_DT papers_NNS reported_VBD very_RB
          specific_JJ criteria_NNS as_IN to_TO population_NN ,_, treatment_NN ,_, laboratory_NN
          methods_NNS ,_, etc_FW ._.
        
        
          Study_NN population_NN
          These_DT different_JJ objectives_NNS influenced_VBD the_DT selection_NN of_IN
          studies_NNS ._. Acceptable_NNP papers_NNS were_VBD limited_VBN to_TO RCT_NNP 's_POS in_IN the_DT
          first_JJ and_CC second_JJ articles_NNS ._. The_DT third_JJ article_NN was_VBD based_VBN on_IN
          case-control_JJ and_CC cohort_NN studies_NNS ,_, since_IN randomized_JJ trials_NNS
          could_MD not_RB be_VB done_VBN for_IN this_DT topic_NN ._. All_DT study_NN designs_NNS were_VBD
          allowable_JJ in_IN example_NN 4_CD (_( the_DT design_NN characteristics_NNS in_IN the_DT
          title_NN refer_VBP to_TO population_NN and_CC protocol_NN differences_NNS ,_, not_RB
          the_DT type_NN of_IN study_NN )_) ._. All_DT four_CD meta-analyses_JJ used_VBN
          additional_JJ inclusion_NN /_NN exclusion_NN criteria_NNS ._. The_DT criteria_NNS in_IN
          paper_NN 1_CD addressed_VBD the_DT subject_NN and_CC control_NN treatments_NNS ._.
          Paper_NNP 2_CD required_VBN double-blind_JJ trials_NNS of_IN at_IN least_JJS 4_CD weeks_NNS
          duration_NN ._. Paper_NNP 3_CD required_VBN clear_JJ differentiation_NN of_IN
          ischemic_JJ stroke_NN from_IN other_JJ strokes_NNS ,_, and_CC at_IN least_JJS 10_CD
          subjects_NNS with_IN a_DT stroke_NN ._. Paper_NNP 4_CD included_VBD all_DT study_NN types_NNS ,_,
          but_CC required_VBD that_IN measures_NNS of_IN association_NN between_IN age_NN and_CC
          T_NN levels_NNS be_VB included_VBN ._. All_DT papers_NNS required_VBN that_IN usable_JJ
          data_NNS be_VB available_JJ ._.
        
        
          Locating_NNP studies_NNS
          Paper_NN identification_NN began_VBD with_IN a_DT Medline_NNP search_NN in_IN
          each_DT study_NN and_CC all_DT authors_NNS cited_VBD review_NN articles_NNS as_IN a_DT
          source_NN of_IN other_JJ references_NNS ._. The_DT authors_NNS in_IN all_DT articles_NNS
          said_VBD that_IN they_PRP had_VBD contacted_VBN investigators_NNS for_IN more_JJR data_NNS ._.
          We_PRP are_VBP sad_JJ to_TO note_VB that_DT example_NN 4_CD reported_VBD that_IN of_IN ten_CD
          authors_NNS contacted_VBN ,_, only_RB one_CD replied_VBD ._.
        
        
          Screening_NNP and_CC evaluation_NN methods_NNS
          Blinding_NNP was_VBD not_RB used_VBN consistently_RB ._. The_DT authors_NNS of_IN
          example_NN 1_CD were_VBD the_DT only_JJ ones_NNS who_WP used_VBD blinded_JJ reviewers_NNS
          in_IN selection_NN and_CC evaluation_NN ._. The_DT question_NN of_IN blinding_VBG was_VBD
          not_RB addressed_VBN in_IN papers_NNS 2_CD and_CC 3_CD ._. Paper_NNP 4_CD reported_VBD
          blinding_VBG for_IN the_DT quality_NN evaluation_NN ._. All_DT papers_NNS reported_VBD
          developing_VBG a_DT quality_NN score_NN ,_, but_CC the_DT quality_NN score_NN in_IN
          example_NN 4_CD was_VBD only_RB on_IN the_DT laboratory_NN methods_NNS ,_, and_CC thus_RB
          was_VBD not_RB describing_VBG the_DT overall_JJ quality_NN of_IN the_DT study_NN ._. In_IN
          examples_NNS 1_CD and_CC 2_CD ,_, the_DT authors_NNS used_VBD the_DT scoring_VBG system_NN of_IN
          Chalmers_NNP [_NN 25_CD ]_NN ,_, while_IN the_DT others_NNS used_VBD simpler_JJR scoring_VBG
          systems_NNS developed_VBN for_IN the_DT study_NN ._. Examples_NNS 1_CD ,_, 2_CD and_CC 3_CD used_VBN
          two_CD raters_NNS ._. Examples_NNS 1_CD and_CC 2_CD required_VBD a_DT consensus_NN
          evaluation_NN ,_, but_CC example_NN 3_CD used_VBD the_DT average_NN of_IN the_DT two_CD
          raters_NNS ._.
          Paper_NNP 1_CD reported_VBD the_DT overall_JJ quality_NN scores_NNS for_IN each_DT
          study_NN included_VBN in_IN the_DT analyses_NNS ._. The_DT authors_NNS used_VBD the_DT
          quality_NN score_NN to_TO divide_VB the_DT studies_NNS into_IN three_CD groups_NNS and_CC
          then_RB compared_VBD the_DT pooled_VBN relative_JJ risk_NN in_IN the_DT three_CD
          groups_NNS ._. In_IN paper_NN 2_CD ,_, the_DT authors_NNS tested_VBD the_DT effect_NN of_IN
          quality_NN scores_NNS by_IN comparing_VBG results_NNS in_IN studies_NNS with_IN
          scores_NNS above_IN and_CC below_IN the_DT median_NN ._. Paper_NNP 3_CD did_VBD not_RB
          describe_VB any_DT quality_NN score_NN and_CC in_IN paper_NN 4_CD a_DT score_NN was_VBD
          developed_VBN for_IN laboratory_NN methods_NNS which_WDT was_VBD used_VBN for_IN
          descriptive_JJ information_NN only_RB ._.
        
        
          Data_NNP abstraction_NN
          Although_IN all_PDT the_DT articles_NNS reported_VBD or_CC implied_VBN
          standardized_JJ data_NNS extraction_NN ,_, none_NN of_IN them_PRP provided_VBD
          examples_NNS or_CC description_NN of_IN the_DT format_NN ._. Paper_NNP 1_CD reported_VBD
          using_VBG two_CD blinded_JJ raters_NNS for_IN data_NNS abstraction_NN ,_, but_CC the_DT
          others_NNS did_VBD not_RB mention_VB blinding_VBG at_IN this_DT point_NN ._.
        
        
          Data_NNP analysis_NN
          Examples_NNS 1_CD -_: 3_CD used_VBN weighted_JJ estimates_NNS of_IN effect_NN size_NN to_TO
          estimate_VB an_DT overall_JJ effect_NN ._. In_IN example_NN 1_CD ,_, the_DT
          investigators_NNS computed_JJ survival_NN statistics_NNS and_CC odds_NNS
          ratios_NNS for_IN response_NN and_CC used_VBD the_DT random_JJ effects_NNS models_NNS [_NN
          32_CD ]_NN to_TO analyze_VB the_DT data_NNS ._. We_PRP note_VBP that_IN in_IN this_DT paper_NN the_DT
          actual_JJ survival_NN statistics_NNS had_VBD to_TO be_VB estimated_VBN from_IN
          summary_NN data_NNS for_IN many_JJ of_IN the_DT studies_NNS ._. The_DT simplest_JJS
          analysis_NN was_VBD in_IN example_NN 2_CD ,_, where_WRB weighted_JJ estimates_NNS of_IN
          the_DT differences_NNS between_IN treated_VBN and_CC untreated_JJ groups_NNS were_VBD
          computed_JJ for_IN pain_NN and_CC disability_NN outcomes_NNS ._. In_IN example_NN 2_CD ,_,
          tests_NNS for_IN heterogeneity_NN were_VBD significant_JJ when_WRB all_PDT the_DT
          studies_NNS were_VBD included_VBN ,_, but_CC became_VBD non-significant_JJ when_WRB
          one_CD study_NN was_VBD excluded_VBN ._. Subanalyses_NNP in_IN example_NN 3_CD looked_VBD
          at_IN the_DT contributions_NNS of_IN other_JJ factors_NNS ,_, such_JJ as_IN smoking_NN
          and_CC alcohol_NN to_TO heterogeneity_NN ._. The_DT analysis_NN in_IN example_NN 4_CD
          focused_VBN on_IN differences_NNS between_IN the_DT testosterone-age_JJ
          correlation_NN in_IN different_JJ patient_NN groups_NNS using_VBG visual_JJ
          display_NN and_CC multiple_JJ regression_NN methods_NNS ._.
        
        
          Reporting_NNP and_CC interpretation_NN
          All_DT papers_NNS gave_VBD details_NNS of_IN all_PDT the_DT studies_NNS that_WDT were_VBD
          included_VBN ._. All_DT examples_NNS made_VBD good_JJ use_NN of_IN graphic_JJ display_NN ._.
          Examples_NNS 1_CD -_: 3_CD included_VBD plots_NNS of_IN the_DT effect_NN size_NN for_IN the_DT
          selected_VBN studies_NNS ,_, while_IN example_NN 4_CD presented_VBN comparison_NN
          plots_NNS of_IN the_DT regression_NN lines_NNS for_IN testosterone_NN on_IN age_NN for_IN
          different_JJ breakdowns_NNS of_IN population_NN characteristics_NNS or_CC
          sampling_VBG times_NNS ._.
        
      
      
        Conclusion_NNP
        In_IN this_DT paper_NN we_PRP have_VBP addressed_VBN the_DT procedures_NNS for_IN
        performing_VBG a_DT meta-analysis_JJ ,_, focusing_VBG primarily_RB on_IN the_DT steps_NNS
        before_IN data_NNS analysis_NN ._. Meta-analysis_NNP cannot_NN be_VB thought_VBN of_IN as_IN
        a_DT quick_JJ and_CC easy_JJ way_NN to_TO pull_VB a_DT lot_NN of_IN studies_NNS together_RB and_CC
        come_VB up_RB with_IN a_DT publication_NN ,_, but_CC like_IN any_DT other_JJ study_NN ,_,
        requires_VBZ an_DT appreciable_JJ investment_NN of_IN time_NN in_IN planning_NN and_CC
        implementation_NN ._. As_IN with_IN any_DT scientific_JJ procedure_NN ,_, there_EX are_VBP
        areas_NNS of_IN controversy_NN ._. A_DT primary_JJ one_CD is_VBZ the_DT inclusion_NN of_IN
        studies_NNS other_JJ than_IN RCT_NNP 's_POS ._. Although_IN this_DT has_VBZ become_VBN more_RBR
        common_JJ in_IN the_DT past_JJ few_JJ years_NNS ,_, it_PRP is_VBZ still_RB controversial_JJ ._. In_IN
        example_NN 3_CD ,_, there_EX were_VBD no_DT RCT_NNP 's_POS for_IN this_DT subject_NN ,_, although_IN
        there_EX had_VBD been_VBN many_JJ observational_NN studies_NNS ._. It_PRP is_VBZ important_JJ
        that_IN ,_, however_RB you_PRP decide_VBP ,_, you_PRP have_VBP a_DT good_JJ reason_NN for_IN your_PRP$
        choice_NN ._.
        Another_DT area_NN of_IN controversy_NN is_VBZ in_IN the_DT homogeneity_NN of_IN the_DT
        studies_NNS ._. We_PRP stated_VBD previously_RB that_IN when_WRB the_DT purpose_NN of_IN a_DT
        meta-analysis_JJ is_VBZ to_TO provide_VB estimates_NNS of_IN specific_JJ effects_NNS ,_,
        then_RB the_DT criteria_NNS for_IN inclusion_NN would_MD be_VB more_RBR restrictive_JJ
        than_IN if_IN the_DT objective_NN were_VBD to_TO model_VB sources_NNS of_IN variability_NN ._.
        In_IN practice_NN ,_, most_RBS meta-analyses_JJ combine_VB both_DT objectives_NNS ._.
        Even_RB if_IN the_DT primary_JJ objective_NN is_VBZ simple_JJ estimates_NNS ,_, there_EX
        are_VBP population_NN effects_NNS that_WDT should_MD be_VB investigated_VBN and_CC
        discussed_VBN ._. One_CD of_IN the_DT benefits_NNS of_IN meta-analysis_JJ is_VBZ that_IN it_PRP
        may_MD be_VB used_VBN to_TO extend_VB conclusions_NNS beyond_IN the_DT frequently_RB
        limited_JJ populations_NNS that_WDT are_VBP included_VBN in_IN a_DT single_JJ study_NN ._.
        Moreover_RB ,_, given_VBN the_DT effort_NN that_WDT goes_VBZ into_IN identifying_VBG and_CC
        evaluating_VBG papers_NNS ,_, ignoring_VBG or_CC rejecting_VBG valuable_JJ
        information_NN is_VBZ wasteful_JJ ._. Dickersin_NNP and_CC others_NNS [_NN 18_CD 34_CD ]_NN
        point_NN out_IN that_IN heterogeneity_NN is_VBZ not_RB all_DT bad_JJ ._. It_PRP improves_VBZ
        the_DT generalizability_NN of_IN the_DT results_NNS of_IN the_DT meta-analysis_JJ ._.
        It_PRP may_MD help_VB to_TO point_VB out_RP factors_NNS that_WDT influence_NN the_DT results_NNS
        of_IN the_DT outcome_NN that_WDT were_VBD not_RB observable_JJ in_IN individual_JJ
        trials_NNS ._. If_IN the_DT effect_NN is_VBZ consistent_JJ even_RB with_IN discrepant_NN
        studies_NNS ,_, it_PRP strengthens_VBZ the_DT case_NN for_IN the_DT causality_NN of_IN the_DT
        treatment_NN ._. If_IN a_DT meta-analysis_JJ is_VBZ performed_VBN prior_RB to_TO
        beginning_VBG a_DT new_JJ study_NN ,_, then_RB heterogeneity_NN may_MD help_VB the_DT
        investigator_NN improve_VB his_PRP$ design_NN by_IN incorporating_VBG an_DT
        understanding_NN of_IN these_DT other_JJ factors_NNS ._.
        We_PRP mention_VBP here_RB that_IN there_EX is_VBZ some_DT leeway_NN to_TO modify_VB your_PRP$
        goals_NNS once_RB original_JJ studies_NNS are_VBP reviewed_VBN ,_, since_IN only_RB then_RB
        will_MD you_PRP know_VB the_DT extent_NN of_IN the_DT data_NNS and_CC which_WDT variables_NNS ,_,
        other_JJ than_IN the_DT primary_JJ effect_NN ,_, have_VBP been_VBN measured_VBN ._. For_IN
        example_NN ,_, you_PRP may_MD find_VB that_IN there_EX is_VBZ an_DT obvious_JJ grouping_VBG of_IN
        study_NN populations_NNS by_IN age_NN or_CC ethnicity_NN ,_, and_CC decide_VB to_TO
        investigate_VB those_DT effects_NNS ._. Such_JJ modifications_NNS should_MD ,_, of_IN
        course_NN ,_, be_VB restricted_VBN to_TO observation_NN of_IN the_DT available_JJ data_NN
        and_CC should_MD not_RB be_VB based_VBN on_IN the_DT results_NNS of_IN preliminary_JJ
        analysis_NN ._.
        In_IN summary_NN ,_, a_DT meta-analysis_JJ is_VBZ an_DT important_JJ and_CC valuable_JJ
        tool_NN for_IN summarizing_VBG data_NNS from_IN multiple_JJ studies_NNS ._. However_RB ,_,
        it_PRP is_VBZ not_RB an_DT easy_JJ task_NN and_CC requires_VBZ careful_JJ thought_NN and_CC
        planning_NN to_TO provide_VB accurate_JJ and_CC useful_JJ information_NN ._.
      
      
        Competing_VBG Interests_NNP
        None_NN declared_VBD ._.
      
      
        Authors_NNP '_'' Contributions_NNP
        Nancy_NNP G_NNP ._. Berman_NNP and_CC Robert_NNP A_DT ._. Parker_NNP collaborated_VBD on_IN the_DT
        conceptualization_NN and_CC writing_NN of_IN this_DT paper_NN ._. Both_DT authors_NNS
        read_VBP and_CC approved_VBD the_DT final_JJ manuscript_NN ._.
      
    
  
